Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis
Canopy Growth reported Q4 FY2026 net revenue of $71.2 million, up 10% year-over-year, driven by 27% growth in Canada medical cannabis and 68% growth in international markets. Full-year revenue reached $284.6 million, a 6% increase, while the net loss from continuing operations narrowed by 49% to $262.9 million. The company ended the fiscal year with $131.3 million in net cash, a significant turnaround from $172.6 million in net debt a year prior. Management expects to achieve positive Adjusted EBITDA in FY2027, citing improved gross margins, cost discipline, and the integration of MTL Cannabis.
Key figures
- Revenue
- 284603000
- Guidance
- Positive Adjusted EBITDA expected in FY2027
- Revenue Yoy
- 6%
- Q4 revenue
- 71245000
- Q4 revenue yoy
- 10%
- Fy gross margin
- 24%
- Q4 gross margin
- 12%
- Net cash position
- 131300000
- Storz bickel revenue q4
- 16782000
- Fy adjusted gross margin
- 28%
- Q4 adjusted gross margin
- 27%
- Canada medical revenue q4
- 25280000
- Storz bickel revenue q4 yoy
- -14%
- Canada medical revenue q4 yoy
- 27%
- International cannabis revenue q4
- 8599000
- Asset impairment restructuring costs
- 67100000
- International cannabis revenue q4 yoy
- 68%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.